Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas

Am J Clin Pathol. 2013 Dec;140(6):795-800. doi: 10.1309/AJCPEBOUJ7GVYVLG.

Abstract

Objectives: To determine whether SOX11 is a diagnostic marker of mantle cell lymphoma (MCL).

Methods: We analyzed SOX11 expression in 349 B-cell non-Hodgkin lymphomas (B-NHLs) via immunohistochemistry.

Results: Nuclear staining of SOX11 was observed in 54 (93.1%) of 58 MCLs. We noticed that SOX11 protein was also expressed on the nuclei in 8 (21.6%) of 37 B-lymphoblastic lymphomas, 45 (32.6%) of 138 diffuse large B-cell lymphomas, 15 (44.1%) of 34 follicular lymphomas, 8 (30.8%) of 26 Burkitt lymphomas, 2 (10.0%) of 20 chronic lymphocytic leukemia/small cell lymphomas, and 3 (18.8%) of 16 marginal zone lymphomas.

Conclusions: Although the positive rate of SOX11 expression in MCL was significantly higher than other B-NHLs (P < .001), polyclonal antibody targeting SOX11 is not able to identify MCL from B-NHLs because the nuclear staining of SOX11 was widely positive in B-NHLs.

Keywords: B-cell non-Hodgkin lymphoma; Immunohistochemistry; Mantle cell lymphoma; Polyclonal antibody; SOX11.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies
  • Biomarkers, Tumor / analysis*
  • Humans
  • Immunohistochemistry
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / metabolism
  • Lymphoma, Mantle-Cell / diagnosis*
  • Lymphoma, Mantle-Cell / metabolism
  • SOXC Transcription Factors / analysis*
  • SOXC Transcription Factors / biosynthesis

Substances

  • Antibodies
  • Biomarkers, Tumor
  • SOX11 protein, human
  • SOXC Transcription Factors